Skip to content

Article

EMEA Leveraged Finance Weekly: Acqua & Sapone Prices €500M FRNs Due 2033; Investors Praise Cedacri Resilience as It Prices €980M SSNs; Adabas & Natural Sole Loan in Slow Week

 

Reporting: Holly Beveridge
Credit Research: Tia Zhang, Rafi Rees

While Europe’s leveraged loan market remained subdued this week, high-yield was back in action following last week’s midterm election and ahead of the impending Thanksgiving break. Leading the charge was Acqua & Sapone with a €500 million issuance, followed by Cedacri and Amplifon. Deals by Odido and Drax rounded out the week, whereas Adabas & Natural was the sole deal in the loan market with a fungible add-on.

In macroeconomic news, the consumer price index, or CPI, for all urban consumers increased 0.4% on a seasonally adjusted basis in October after rising 0.6% in September, according to the United States Bureau of Labor Statistics. This was slightly hotter than the 0.3% expected.

Speaking in London before the inflationary print, U.S. Federal Reserve Christopher Waller made the case for a further tightening of monetary policy, warning that inflation remains too high.

“Federal Reserve staff have been thinking hard about the effects on inflation of the AI buildout and elevated energy prices, and their findings do not encourage me to think that these factors will be fading anytime soon,” Waller said.

“Some other Fed research indicates to me that energy price pressures may pass through to goods and services in a more sustained way than in the past,” he added. “Central bankers have tended to look through energy price shocks and expect that their effects on inflation will soon fade, but this new work cautions against taking too much comfort in this view. Their analysis suggests that, especially if oil prices were to remain elevated, these pressures could be larger than previously thought and persist well into 2027.”

Eurozone government yield bonds reacted strongly to the CPI reading. Today, Nov. 13, the benchmark German 10-year Bund yield climbed to a two-week high of 3.357%, while at the front of the curve, the two-year German yield was at about 3.155%.


Request a demo of Octus Leveraged Finance Solution >

 


Acqua & Sapone Prices €500M FRNs Due 2033 at E+350 Bps, Investors Mixed on Business

Investors had mixed views on Italian non-food value retailer Acqua & Sapone’s €500 million senior secured floating-rate notes due 2033, which priced at Euribor+350 bps, tightened from price talk of E+375-400 bps. The notes will be used to repay Acqua and Sapone’s existing €475 million senior secured FRNs, and to partially repay drawings under the senior secured RCF.

Two investors agreed that initial price talk, or IPT, looked fair, with the second buy-sider adding that the yield made sense given the extension to the note’s maturity date. However, others were less convinced. A third buy-sider noted that IPT looked tight, while a fourth buy-sider said that their own cut-off for playing the deal was E+400 bps or above, adding that the issuance should come at a premium to comparable Kiko Milano by a range of between 75 and 100 bps.

The same investor was unimpressed by Acqua & Sapone as a business despite the group showing good growth, and was cautious about playing retail in such a competitive market. He also flagged the group’s highly levered capital structure and cash burn on a reported EBITDA basis as reasons for concern.

Other investors were more complimentary, and said that Acqua & Sapone remains highly resilient, even in economic downturns. According to one buy-sider, the business model has delivered stable revenues, predictable capital expenditure and return on equity.

Further Octus coverage is available HERE.

Investors Praise Resilience as Cedacri Prices €980M SSNs Due 2031 at 7.5%, E+362.5 Bps

Investors were keen to play a bumper €980 million new notes offering from banking solutions provider Cedacri, despite some initial caution on pricing. The issuance was split between €630 million senior secured notes, which priced at 7.5%, and €350 million FRNs, which priced at E+362.5 bps. Both tranches are due 2031.

Despite sensitivity around pricing, buy-siders overall liked the business, with one describing it as one of the best assets under the ION Group umbrella, with a decent moat and sticky revenues. He also highlighted there was no big renewal risk, adding that organic top-line growth is broadly flat.

A second buy-sider also praised Cedacri in comparison with ION peers, noting the business was going in a positive direction, with long locked contracts, good cash generation, sensible deleveraging plans and caps to shareholder dividends.

That said, another buy-sider raised worries about parent ION’s €2.5 billion HoldCo debt, and how much cash was leaked from the companies underneath to service it, an issue that has been long on top of investor minds. He also said that the company had no real levers to deleverage, as excess free cash flow is upstreamed to service HoldCo interest.

Further Octus coverage is available HERE.

Amplifon Prices €600M SUNs Due 2031, Investors Positive on Business, Cautious on Pricing

Italian hearing care retailer Amplifon priced €600 million senior unsecured notes due 2032 at 4.875%, tightened from IPT of between 5.25% and 5.50%. Proceeds will be used to finance the acquisition from the hearing business from GN Store Nord A/S, and to redeem existing €350 million SUNs due February 2027.

Investors broadly liked Amplifon, seeing it as a safe business model in which consumers must periodically replace and upgrade their hearing aids. However, several buy-siders said they would skip the company’s recently announced €600 million senior unsecured notes, or SUNs, due 2031, with one high-yield analyst noting that he expected the deal to price too tight for it to be appealing.

One investor looking at the deal liked that the hearing aids market was growing, noting that this bodes well for the company’s future growth. His concerns centered on the slightly elevated net leverage of 3.7x, and the current pressures on consumers, which affects spending power.

Further Octus coverage is available HERE.

Odido Prices Dual-Tranche €900M Offering Due 2032; Drax Prices Upsized €1B SSNs

Elsewhere, business-to-consumer mobile postpaid operator Odido priced a €900 million offering due 2032. The issuance was split between €500 million fixed-rate SSNs, priced at 6.5%, and €400 million floating-rate SSNs, priced at E+325 bps. Final pricing tightened from fixed-rate IPT of 7-7.25%, and floating-rate IPT of E+375 bps.

Power generation company Drax Group’s subsidiary, Drax Finco, was also out in the market. The company priced an offering of €1 billion in 5.5-year SSNs at 5.875%, upsized from €650 million, and tightened from IPT of low-to-mid-6s.

Adabas & Natural Launches €180M Add-On of Fungible TLB in Quiet Week for Leveraged Loans

Against a busy week for high yield, the European leveraged loan market was comparatively quiet. The sole transaction in the market was an add-on by Adabas & Natural, fka Software AG, a software company sponsored by Silver Lake. The business, which provides database and infrastructure software for high-volume, transaction-intensive enterprise workloads, launched a €180 million fungible term loan B add-on. Price talk as of Nov. 10 was at E+375 bps, in line with the existing loan, with OID in the 97.5 area. Proceeds will be used for general corporate purposes.
 

To see the covenant analysis of any primary deals or to talk to one of our legal analysts, contact us at [email protected] or [email protected]

 

High-Yield Bonds

 

 

 

 

 

 

Leveraged Loans

 

See all these deal signals before the rest of the market.

Request a demo of Octus Leveraged Finance Solution

Share this article

This publication has been prepared by Octus Intelligence, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2026 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.